NeuroPain kick-off meeting (Barcelona, Spain, 7-9 January 2014) NeuroPain kick-off meeting (Barcelona, Spain, 7-9 January 2014)

Venue: Barcelona Biomedical Research Park (PRBB), c/ Dr. Aiguader, 88, 08003 Barcelona

This meeting gathered all partners of the NeuroPain consortium as well as the EC legal officer, Petra Tonova. An overview of the project's objectives and workpackages was given and fruitful discussion about the forthcoming results was also carried out.

 

Parc de Recerca Biomèdica

NeuroPain Executive Board meeting (Reykjavik, Iceland, 19th September 2014) NeuroPain Executive Board meeting (Reykjavik, Iceland, 19th September 2014)

Venue: deCODE Genetics

This meeting gathered all partners of the NeuroPain consortium. Preliminary results from preclinical experiments and detailed information on the clinical studies planned were presented.

 

Decode Genetics Building

 

Annual General Meeting (AGM) NeuroPain (London, UK, 16th-17th June, 2015) Annual General Meeting (AGM) NeuroPain (London, UK, 16th-17th June, 2015)

Venue: Medical Sciences G46 H O Schild Pharmacology LT, UCL.

This meeting gathered all partners of the NeuroPain consortium, including posters presentations from young investigators of the consortium. Further progress in preclinical experiments and the approval packages, including the design of the different clinical studies, were presented.

NeuroPain Executive Board Meeting (Bonn, Germany, 7-8th January, 2016) NeuroPain Executive Board Meeting (Bonn, Germany, 7-8th January, 2016)

Venue: The Institute of Molecular Psychiatry. Life & Brain Building, Seminar room, ground floor. Sigmund-Freud-Str. 25, 53127 Bonn, Germany.

This meeting gathered the PIs of all partners of the NeuroPain consortium. Preclinical studies to be conducted using genetically-modified animals (including conditional knockout mice) was discussed and planned. Further progress in the different clinical studies was assessed.

AGM NeuroPain meeting (Barcelona, Spain, 20th-21th June, 2016) AGM NeuroPain meeting (Barcelona, Spain, 20th-21th June, 2016)

Venue: Antonio Caparrós Auditorium, in Tower D of the Parc Científic de Barcelona (Barcelona Science Park, D-Tower).

This meeting gathered all partners of the NeuroPain consortium, including posters presentations from young investigators of the consortium. Final results from behavioural studies and very advanced results of preclinical regulatory studies of candidate analgesic compounds were presented. Mid-term recruitment results of the different clinical studies were presented, including discussion on and approval of an amendment to the EC regarding those studies.

NeuroPain Executive Board meeting (Strasbourg, France, 7-8th January, 2017) NeuroPain Executive Board meeting (Strasbourg, France, 7-8th January, 2017)

Venue: Meeting room nr. CBI-1031. IGBMC. Translational Medicine and Neurogenetics Dpt. 1 rue Laurent Fries, BP 10142, 67404 Illkirch, France.

This meeting gathered the PIs of all partners of the NeuroPain consortium. The effects of the recently amendment approved by the EC was discussed.

AGM NeuroPain (Krakow, Poland 29 June 1 July, 2017) AGM NeuroPain (Krakow, Poland 29 June 1 July, 2017)

Venue: Galaxy Hotel, Krakow, Poland.

This meeting gathered all partners of the NeuroPain consortium, including posters presentations from young investigators of the consortium. The translational value of preclinical results, as compared to those from clinical studies, and the need of further efforts for an efficient validation of findings across species, were discussed. The final design of the interventional clinical study was released and a subsequent amendment to the EC to cover this new design was discussed and approved.

Neuropain Executive board meeting (Berlin, Germany, 12-13th February, 2018) Neuropain Executive board meeting (Berlin, Germany, 12-13th February, 2018)

Venue: Charité Hospital, Campus Benjamin Franklin (CBF). Entrance West, Room “Kursraum 1”. Hindenburgdamm 30. 12203 Berlin.

This meeting gathered the PIs of all partners of the NeuroPain consortium. Preclinical studies had been almost completed, as well as the preclinical evaluation of the different analgesic compounds, yielding a clear choice. The two observational clinical studies had been also completed and the clinical trial was running according to the recently EC-granted amendment, which is supposed to greatly contribute to reaching the planned target.

AGM NeuroPain meeting (Helsinki, Finland, 14-16th October, 2018) AGM NeuroPain meeting (Helsinki, Finland, 14-16th October, 2018)

Venue: Hanasaari (Hanaholmen) Swedish-Finnish Cultural Centre-Hotel, Hanasaarenranta 5, 02100 Espoo (Finland).

This meeting gathered all partners of the NeuroPain consortium, including posters presentations from young investigators of the consortium. Final results of preclinical and clinical studies, including biomarkers, were discussed. The grounds for a final report and publication of the results obtained were discussed and approved by al partners.

Other scientific meetings Other scientific meetings

Society for Neuroscience (Washington D.C., USA, 15-19th November, 2014)

The EC delegation is organising a booth at this conference. Material of the NeuroPain project (flyer) will be available for distribution to support the dissemination of projects objectives. One of the PIs, Eija Kalso (partner 10) will be also attending this event.

 

Lecture of R. Maldonado (partner 1) to Primary School students on the effect of psychoactive drugs in the brain, in the frame of the Youth Mobile Festival (YOMO) of the World Mobile Congres (MWC), Barcelona (27/2-2/3-2017).

 

Participation of different members of Partner 1 (Laboratory of Neuropharmacology) in an interactive workshop on the effect of drugs in the brain and on the neurobiological substrate of several neuropsychiatric disorder, including pain, adressed to Primary and Secondary School students in the frame of the Youth Mobile Festival (YOMO) of the World Mobile Congress (MWC), Barcelona (27/2-2/3-2017). Press impact: El Economista and La Vanguardia (24/2/2017)

 

 

Dissemination activities Dissemination activities

1. Flyers. UNIVERSITAT POMPEU FABRA . Consortium leaflet that was requested by the EC to be presented at the Society for Neuroscience meeting. 15/11/2014. Washington, USA.                       

2. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. PhD Thesis R. Negrete. Role of the endogenous opioid system in drug addiction and in eating disorders. 16/12/2016. Barcelona, Spain.               

3. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. PhD Thesis IM. Lara-Mayorga. Involvement of the endocannabinoid system in the nociceptive, emotional and cognitive components of neuropathic pain. 12/07/2017. Barcelona, Spain.

4. Oral presentation to a scientific event. ISLENSK ERFDAGREINING EHF. PhD Thesis V. Bjarnadottir. Conditioned pain modulation in chronic pain vs controls - physical and psychological components (in Icelandic). 01/02/2015. Reykjavik. 

5. Oral presentation to a scientific event. ISLENSK ERFDAGREINING EHF. PhD Thesis B.H. Hardarson. Association of inflammatory cytokines and neurotrophic factors with pain sensitization (in Icelandic). 01/03/2015. Reykjavik.              

6. Oral presentation to a scientific event. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. PhD Thesis. R. Sipilä. Pain sensitivity and factors associated with the pain experience after breast cancer treatments. 01/06/2018. Helsinki.    

7. Posters. UNIVERSITAT POMPEU FABRA. 1st European Pain Federation-EFIC Topical Symposium on Acute and Chronic Joint Pain. 01/11/2014. Dubrovnik, Croatia.       

8. Posters. UNIVERSITAT POMPEU FABRA. Mice with neuropathic pain self-administer a CB2 agonist with antinociceptive and anxiolytic properties. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.

9. Posters. Laboratorios del Dr Esteve, SA. Analgesic effect of the selective simga1 receptor antagonist E52862 in a rat model of osteoarthritis pain: possible role in NMDA regulation. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.

10. Posters. Laboratorios del Dr Esteve, SA. Sigma 1 receptors are necessary for the development and expression of depressive like behavior as a consequence of neuropathic pain in mice. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.         

11. Posters. Laboratorios del Dr Esteve, SA. Discovery and characterization of a first-in-class co-crystal of tramadol-celecoxib in development for the treatment of moderate to severe acute pain. 27/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.         

12. Posters. Laboratorios del Dr Esteve, SA. Administration of Tramadol and Celecoxib in a 1:1 molecular ratio produces synergistic antinociceptive effects in postoperative pain models: preclinical rationale for clinical development of crystal of tramadol-celecoxib. 27/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.           

13. Posters. Laboratorios del Dr Esteve, SA. Pharmacokinetic profile of multiple doses of cocrystal of tramadol-celecoxib: finding from an open-label, four-period, four-sequence, cross-over, phase I clinical trial in healthy male and female volunteers. 26/09/2018.16th World Congress on Pain - IASP. Yokohama, Japan.              

14. Posters. Laboratorios del Dr Esteve, SA. Cocrystal of tramadol-celecoxib: efficacy and safety results from a dose-finding, randomized, double-blind, multi-center, phase II clinical trial in patients with moderate-to-severe acute pain due to an oral surgical procedure. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.            

15. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Spironolactone, eplerenone, chlorothiazide, furosemide, and opioids: antinociceptive actions and interactions in the rat. 26/09/2018            16th World Congress on Pain - IASP. Yokohama, Japan        

16. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Anger expression and its relations to depression, anxiety, and pain in patients treated for breast cancer. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan           

17. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Modulation of morphine-induced antinociception in acute and chronic opioid treatment by ketamine, norketamine, and hydroxynorketamine  . 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.              

18. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Cold water test and analgesia nociception index in women operated for breast cancer. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan               

19. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Genetic variation in ADRB2 and pain. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.     

20. Posters. IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE. Quantitative sensory testing in the hand: normative data for radial and median nerve are not equivalent. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.

21. Posters. IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE. A systematic review of factors influencing placebo response in clinical trials of neuropathic pain: a comparison of HIV associated sensory neuropathy and diabetic polineuropathy. 26/09/2018.     16th World Congress on Pain - IASP. Yokohama, Japan.

22. Posters. IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE. Correlation between corneal confocal microscopy and quantitative sensory testing parameters in a multicentre, mixed aetiology neuropathy cohort. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.

23. Posters. UNIVERSITAT POMPEU FABRA. E52862, a sigma1 receptor antagonist, inhibits mechanical hypersensitivity and restores morphine analgesia in a mouse model of osteoarthritis pain. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan            .

24. Posters. UNIVERSITAT POMPEU FABRA. Influence of behavioural traits in the interindividual variation of nociceptive, emotional and cognitive manifestations of neuropathic pain. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.

25. Posters. UNIVERSITY COLLEGE LONDON. Influence of 5HT serotonin receptors in the emotional component of neuropathic pain in rats. 26/09/2018.    16th World Congress on Pain - IASP. Yokohama, Japan .

26. Posters. UNIVERSITY COLLEGE LONDON. Investigating diffuse noxious inhibitory controls (DNIC) in a monoiodoacetate (MIA) rat model of osteoarthritis. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.               

27. Posters. UNIVERSITY COLLEGE LONDON. Neuronal hyperexcitability in the ventro-basal- thalamic complex of neuropathic rats is partially reversed by pregabalin. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.

28. Posters. UNIVERSITAT POMPEU FABRA. Effects of Pregabalin on the nociceptive: emotional and cognitive manifestations of neuropathic pain in mice. 26/09/2018. 16th World Congress on Pain - IASP. Yokohama, Japan.               

29. Posters. IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE. Longitudinal changes in sensory profiles of HIV positive patients with and without HIV-associated neuropathy. 05/04/2018. British HIV association annual conference in Manchester, UK.

30. Posters. UNIVERSITY COLLEGE LONDON. The temporal stability of conditioned pain modulation over time in healthy male volunteers. 01/06/2015. NeuPSIG conference. Nice, France.

31. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Risk factors for acute postoperative pain after breast cancer surgery. 02/09/2015. 9th Congress of the European Pain Federation (EFIC) in Wien, Austria.  

32. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Intercostobrachial nerve resection in breast cancer surgery: patients with and without neuropathic pain 4 to 9 years after. 04/06/2017. 6th International Congress on Neuropathic Pain (NeuPSIG). Gothenburg, Sweden.         

33. Oral presentation to a scientific event. IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE. Pain in HIV - A global perspective. 26/09/2018. Workshop 16th World Congress on Pain - IASP. Yokohama, Japan.      

34. Oral presentation to a scientific event. IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE. Conditioned pain modulation: rising star in personalised care or experimental nightmare. 01/07/2018. Anaesthesia section of the Royal College of Medicine.

35. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Pain and discomfort during three years following breast cancer surgery. 03/09/2017. 10th Congress of the European Pain Federation (EFIC) in Copenhagen, Denmark.

36. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Psychological resilience explains differences in pain severity and pain interference. 03/09/2017. 10th Congress of the European Pain Federation (EFIC) in Copenhagen, Denmark.             

37. Posters. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Cognition in women 4 to 9 years after treatment for breast cancer. 05/09/2017. 6th Scientific Congress of the Federation of the European Societies of Neuropsychology (FENS).          

38. Oral presentation to a scientific event. CHARITE - UNIVERSITAETSMEDIZIN BERLIN. Utilization of different questionnaires and screening tools for assessment of neuropathic pain. 15/06/2017. 6th International Congress on Neuropathic Pain (NeuPSIG). Gothenburg, Sweden.

39. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. Role of CB1 and CB2 cannabinoid receptors in the emotional and cognitive alterations associated with osteoarthritis pain. 08/09/2014. 24th Annual International Cannabinoid Research Society (ICRS) Symposium on the Cannabinoids.

40. Organisation of Conference. UNIVERSITAT POMPEU FABRA. Neuropain Annual General Meeting. Host partner: UPF. 07/09/2014. Barcelona, Spain.

41. Organisation of Conference. UNIVERSITY COLLEGE LONDON. Neuropain Annual General Meeting. Host partner: University College London. 16/06/2015. London, UK.

42. Organisation of Conference. Laboratorios del Dr Esteve, SA . Neuropain Annual General Meeting. Host partner: Laboratorios Dr Esteve. 20/06/2016. Barcelona, Spain

43. Organisation of Conference. INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK Neuropain Annual General Meeting. Host partner: Instiytut Framakologii Polskiej Akademi Nauk. 01/07/2017. Krakow, Poland.

44. Organisation of Conference. HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ. Neuropain Annual General Meeting. Host partner: Helsinkgin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä. 15/10/2018. Helsinki, Finland.

45. Oral presentation to a scientific event. ISLENSK ERFDAGREINING EHF. NeuroPain Executive Board Meeting. 19/09/2014. Reykjavik, Iceland.

46. Oral presentation to a scientific event. UNIVERSITAETSKLINIKUM BONN. NeuroPain Executive Board Meeting. 07/01/2015. Bonn, Germany              

47. Oral presentation to a scientific event. CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE. Neuropain Executive Board Meeting. 08/01/2017. Strasbourg, France.

48. Oral presentation to a scientific event. CHARITE - UNIVERSITAETSMEDIZIN BERLIN. NeuroPain Executive Board Meeting. 12/02/2018. Berlin. Germany.

49. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. Involvement of the kappa/dynorphin system in the emotional manifestations of osteoarthritic pain. Oral session 9 (KOR effects on pain & itch). 24/04/2015. The therapeutic potential of kappa opioids in pain and addicion. Chapel Hill, North Carolina, USA. 

50. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. Involvement of the endocannabinoid system in drug addiction. 21/04/2015. Seminar at the Virgina Commonwealth University. Richmond, VA, USA.   

51. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. Mechanisms involved in the cognitive impairment of cannabinoids.     27/05/2015. Gordon Research Conference on Cannabinoid function in the CNS. Lucca, Italy.               

52. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. Role of the mTOR pathway in cognitive impairment induced by cannabinoids. 01/09/2015. European Collegium of Neuropsychopharmacology (ECNP), Amsterdam, The Netherlands.           

53. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. Involvement of the endocannabinoid system in addictive behaviour. 04/04/2016. American Society for Pharmacology & Experimental Therpeutics (ASPET), San Diego, CA, USA.

54. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. Opioid receptors and drug-seeking behaviour. 11/07/2016. International Narcotics Research Conference (INRC), Bath, UK.  

55. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. Cannabinoids for joint pain: insights from mouse models. 03/09/2016. Irish Pain Annual Society Meeting, Dublin, Ireland.            

56. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. The endocannabinoid system: therapeutic perspectives and risks of cannabis consumption. 23/11/2016. Workshop narcotics: problems and solutions, The Pontifical Academy of Sciences, Vatican City, Italy.            

57. Oral presentation to a scientific event. CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE. Opiates and the brain. 23/11/2016. Workshop narcotics: problems and solutions, The Pontifical Academy of Sciences, Vatican City, Italy.               

58. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. The endocannabinoid system and neuropathic pain. 06/09/2017. 10th Congress of the European Pain Federation (EFIC), Copenhagen, Denmark.

59. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. Involvement of the endocannabinoid system in addictive behaviour. 31/05/2018. Biennal Meeting of the Addictive Chapter of the Italian Society of Pharmacology, Verse, Italy.     

60. Oral presentation to a scientific event. UNIVERSITAT POMPEU FABRA. The endocannabinoid system and pain. 25/06/2018. MED Cannabis, Vienna, Austria.